Benjamin G. Neel

Q: What Schools Are Affiliated With Benjamin G. Neel

Benjamin G. Neel is affiliated with the following schools: Yale University, University of Toronto, New York University, Brigham Young University, Harvard University

Benjamin G. Neel's AcademicInfluence.com Rankings

Benjamin G. Neel

Philosophy

#4125

World Rank

#6521

Historical Rank

Logic

#1656

World Rank

#2462

Historical Rank

philosophy Degrees

Benjamin G. Neel

Biology

#5291

World Rank

#7736

Historical Rank

Biochemistry

#611

World Rank

#703

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Benjamin G. Neel's Degrees

Doctorate Medicine Harvard University

Why Is Benjamin G. Neel Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Benjamin G. Neel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

SH2 domains recognize specific phosphopeptide sequences (1993) (2618)
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. (1999) (2045)
Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis (1981) (1421)
Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-Deficient Mice (2000) (1206)
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. (2003) (1167)
STAT3 signalling is required for leptin regulation of energy balance but not reproduction (2003) (1007)
Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals (1995) (980)
Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. (1993) (940)
Protein tyrosine phosphatases in signal transduction. (1997) (784)
PTP1B regulates leptin signal transduction in vivo. (2002) (763)
Germline gain-of-function mutations in SOS1 cause Noonan syndrome (2007) (666)
Neuronal PTP1B regulates body weight, adiposity and leptin action (2006) (595)
The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence (1992) (578)
From Form to Function: Signaling by Protein Tyrosine Phosphatases (1996) (550)
Mathematical models of protein kinase signal transduction. (2002) (515)
Combinatorial control of the specificity of protein tyrosine phosphatases. (2001) (512)
Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia (2004) (472)
Avian leukosis virus-induced tumors have common proviral integration sites and synthesize discrete new RNAs: oncogenesis by promoter insertion (1981) (469)
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression (2017) (462)
Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. (2004) (451)
Imaging Sites of Receptor Dephosphorylation by PTP1B on the Surface of the Endoplasmic Reticulum (2002) (444)
Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation (2004) (415)
The "Gab" in signal transduction. (2003) (384)
Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair (2017) (382)
Critical role for Gab2 in transformation by BCR/ABL. (2002) (379)
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity (2019) (377)
Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. (1994) (374)
Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1 (1995) (372)
Divergent Roles of SHP-2 in ERK Activation by Leptin Receptors* (2001) (365)
The tyrosine phosphatase Shp2 (PTPN11) in cancer (2008) (360)
Protein-tyrosine Phosphatase 1B Expression Is Induced by Inflammation in Vivo* (2008) (358)
Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress (2013) (353)
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance (2016) (350)
Essential role for Gab2 in the allergic response (2001) (343)
The spliceosome is a therapeutic vulnerability in MYC-driven cancer (2015) (342)
Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. (1992) (342)
The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early xenopus development (1995) (335)
Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. (1998) (330)
Molecular cloning of cDNAs encoding a guanine-nucleotide-releasing factor for Ras p21 (1992) (328)
Essential gene profiles in breast, pancreatic, and ovarian cancer cells. (2012) (319)
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects* (2006) (309)
Leptin and Insulin Act on POMC Neurons to Promote the Browning of White Fat (2015) (305)
Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis (2000) (303)
Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor. (1993) (298)
New Role for Shc in Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway (2000) (284)
Isolation of a src homology 2-containing tyrosine phosphatase. (1992) (282)
Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. (1998) (282)
Two human c-onc genes are located on the long arm of chromosome 8. (1982) (275)
Diverse Biochemical Properties of Shp2 Mutants (2005) (270)
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. (2005) (269)
Receptor-Specific Regulation of Phosphatidylinositol 3′-Kinase Activation by the Protein Tyrosine Phosphatase Shp2 (2002) (268)
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. (2004) (263)
Regulation of Receptor Tyrosine Kinase Signaling by Protein Tyrosine Phosphatase-1B* (2003) (259)
SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130* (2003) (256)
The role of Shp2 (PTPN11) in cancer. (2007) (250)
Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression (1996) (248)
High frequency of retinoic acid receptor beta abnormalities in human lung cancer. (1991) (245)
B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. (2007) (244)
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. (2011) (241)
Regulation of Early Events in Integrin Signaling by Protein Tyrosine Phosphatase SHP-2 (1999) (241)
An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. (2006) (240)
Liver-Specific Deletion of Protein-Tyrosine Phosphatase 1B (PTP1B) Improves Metabolic Syndrome and Attenuates Diet-Induced Endoplasmic Reticulum Stress (2009) (239)
Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1 (1996) (229)
Tumor-initiating cells are rare in many human tumors. (2010) (224)
A Role for Nuclear PTEN in Neuronal Differentiation (2000) (224)
Identification of Major Binding Proteins and Substrates for the SH2-Containing Protein Tyrosine Phosphatase SHP-1 in Macrophages (1998) (221)
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells (2011) (219)
Direct identification of PTEN phosphorylation sites (2002) (218)
A role for the scaffolding adapter GAB2 in breast cancer (2006) (216)
Stops along the RAS pathway in human genetic disease (2006) (212)
Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. (1994) (211)
Intramolecular regulation of protein tyrosine phosphatase SH-PTP1: a new function for Src homology 2 domains. (1994) (210)
Identification of an early-growth-response gene encoding a novel putative protein kinase (1992) (208)
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. (2007) (203)
Tyrosyl Phosphorylation of Shp2 Is Required for Normal ERK Activation in Response to Some, but Not All, Growth Factors* (2003) (200)
The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. (2005) (195)
NMR-based functional profiling of RASopathies and oncogenic RAS mutations (2013) (188)
Cloning of a cDNA for a major human protein-tyrosine-phosphatase. (1990) (186)
Nonreceptor protein-tyrosine phosphatases in immune cell signaling. (2007) (185)
MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. (2011) (184)
Coordinated Regulation of Insulin Signaling by the Protein Tyrosine Phosphatases PTP1B and TCPTP (2005) (181)
Cancer genomics: technology, discovery, and translation. (2012) (181)
A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. (1996) (178)
Transgenic Overexpression of Protein-tyrosine Phosphatase 1B in Muscle Causes Insulin Resistance, but Overexpression with Leukocyte Antigen-related Phosphatase Does Not Additively Impair Insulin Action* (2004) (172)
Tyrosyl phosphorylation and growth factor receptor association of the human corkscrew homologue, SH-PTP2. (1993) (171)
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. (2018) (170)
Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance. (2011) (170)
Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site (2015) (168)
Improved Glucose Homeostasis in Mice with Muscle-Specific Deletion of Protein-Tyrosine Phosphatase 1B (2007) (168)
Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. (2012) (165)
Global Proteomic Assessment of the Classical Protein-Tyrosine Phosphatome and “Redoxome” (2011) (162)
Lck-dependent tyrosyl phosphorylation of the phosphotyrosine phosphatase SH-PTP1 in murine T cells (1994) (158)
Role of phosphatases in lymphocyte activation. (1997) (158)
Next-generation sequencing identifies rare variants associated with Noonan syndrome (2014) (156)
Mammalian SH2-Containing Protein Tyrosine Phosphatases (1996) (146)
Genetic analysis of protein tyrosine phosphatases. (1998) (145)
Live-Cell Imaging of Enzyme-Substrate Interaction Reveals Spatial Regulation of PTP1B (2007) (144)
FcγRIII-Dependent Inhibition of Interferon-γ Responses Mediates Suppressive Effects of Intravenous Immune Globulin (2007) (144)
SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. (2006) (142)
The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1 (1998) (141)
Control of CNS Cell-Fate Decisions by SHP-2 and Its Dysregulation in Noonan Syndrome (2007) (140)
Liver-specific Protein-tyrosine Phosphatase 1B (PTP1B) Re-expression Alters Glucose Homeostasis of PTP1B–/–Mice* (2005) (131)
Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance (2001) (129)
SH-PTP2/Syp SH2 domain binding specificity is defined by direct interactions with platelet-derived growth factor beta-receptor, epidermal growth factor receptor, and insulin receptor substrate-1-derived phosphopeptides. (1994) (128)
Structure and function of SH2-domain containing tyrosine phosphatases. (1993) (123)
Structural Determinants of SHP-2 Function and Specificity in Xenopus Mesoderm Induction (1998) (122)
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. (2009) (122)
Critical role for scaffolding adapter Gab2 in FcγR-mediated phagocytosis (2003) (121)
PTP-1B is an essential positive regulator of platelet integrin signaling (2005) (121)
TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. (2011) (120)
Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma (2019) (119)
Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation (2009) (119)
Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. (2010) (117)
Activated Mutants of SHP-2 Preferentially Induce Elongation of Xenopus Animal Caps (2000) (115)
The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. (2000) (113)
Regulation of protein tyrosine phosphatase 1B by sumoylation (2007) (112)
Vitamin C in Stem Cell Reprogramming and Cancer. (2018) (110)
Overexpression of Protein-tyrosine Phosphatase-1B in Adipocytes Inhibits Insulin-stimulated Phosphoinositide 3-Kinase Activity without Altering Glucose Transport or Akt/Protein Kinase B Activation* (2000) (108)
SHPS-1 is a scaffold for assembling distinct adhesion-regulated multi-protein complexes in macrophages (1999) (108)
Sialic Acid Binding Domains of CD22 Are Required For Negative Regulation of B Cell Receptor Signaling (2002) (108)
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature (2012) (106)
Ptpn11 Deletion in A Novel Cartilage Cell Causes Metachondromatosis by Activating Hedgehog Signaling (2013) (106)
Site-Selective Regulation of Platelet-Derived Growth Factor β Receptor Tyrosine Phosphorylation by T-Cell Protein Tyrosine Phosphatase (2004) (106)
Specific modulation of ectodermal cell fates in Xenopus embryos by glycogen synthase kinase. (1995) (104)
Wolfram Syndrome protein, Miner1, regulates sulphydryl redox status, the unfolded protein response, and Ca2+ homeostasis (2013) (102)
CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity (2004) (100)
The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer (2002) (99)
Distinct roles for neutrophils and dendritic cells in inflammation and autoimmunity in motheaten mice. (2013) (99)
Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation. (2010) (98)
SHP-1 negatively regulates neuronal survival by functioning as a TrkA phosphatase (2003) (98)
SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. (2011) (96)
The Scaffolding Adapter Gab2, via Shp-2, Regulates Kit-evoked Mast Cell Proliferation by Activating the Rac/JNK Pathway* (2006) (96)
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back (2010) (94)
Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. (2011) (93)
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2020) (92)
A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome. (2017) (90)
Measles Virus (MV) Hemagglutinin: Evidence that Attachment Sites for MV Receptors SLAM and CD46 Overlap on the Globular Head (2004) (88)
Localization of c-ras oncogene family on human germ-line chromosomes. (1983) (88)
Characterization of Two SHP-2-associated Binding Proteins and Potential Substrates in Hematopoietic Cells* (1997) (87)
Corrigendum: Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling (2014) (86)
Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial (2013) (86)
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. (2015) (85)
Shp1 regulates T cell homeostasis by limiting IL-4 signals (2013) (83)
Regulation of B cell signal transduction by SH2-containing protein-tyrosine phosphatases. (1998) (83)
Substrate specificity of protein tyrosine phosphatases 1B, RPTPα, SHP-1, and SHP-2. (2011) (83)
Evidence for impaired retinoic acid receptor-thyroid hormone receptor AF-2 cofactor activity in human lung cancer (1995) (82)
Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function. (2013) (81)
Scaffolding Adapter Grb2-Associated Binder 2 Requires Syk to Transmit Signals from FcεRI1 (2006) (79)
Deletion of Ptpn11 (Shp2) in Cardiomyocytes Causes Dilated Cardiomyopathy via Effects on the Extracellular Signal–Regulated Kinase/Mitogen-Activated Protein Kinase and RhoA Signaling Pathways (2008) (79)
Protein-tyrosine Phosphatase SHP-1 Is Dispensable for FcγRIIB-mediated Inhibition of B Cell Antigen Receptor Activation* (1997) (79)
Regulation of In Vitro and In Vivo Immune Functions by the Cytosolic Adaptor Protein SKAP-HOM (2005) (79)
Expression, purification, and characterization of SH2-containing protein tyrosine phosphatase, SH-PTP2. (1993) (78)
Mechanism and treatment for the learning and memory deficits associated with mouse models of Noonan syndrome (2014) (78)
FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. (2007) (77)
The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1. (2014) (75)
Neuronal Protein Tyrosine Phosphatase 1B Deficiency Results in Inhibition of Hypothalamic AMPK and Isoform-Specific Activation of AMPK in Peripheral Tissues (2009) (75)
Cell Surface Profiling Using High-Throughput Flow Cytometry: A Platform for Biomarker Discovery and Analysis of Cellular Heterogeneity (2014) (71)
Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome (2015) (71)
Islet-sparing effects of protein tyrosine phosphatase-1b deficiency delays onset of diabetes in IRS2 knockout mice. (2004) (70)
A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. (2010) (69)
PTP1B regulates Eph receptor function and trafficking (2010) (68)
Cutting Edge: Gab2 Mediates an Inhibitory Phosphatidylinositol 3′-Kinase Pathway in T Cell Antigen Receptor Signaling1 (2000) (68)
Adipocyte-Specific Protein Tyrosine Phosphatase 1B Deletion Increases Lipogenesis, Adipocyte Cell Size and Is a Minor Regulator of Glucose Homeostasis (2012) (66)
Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor (2017) (66)
Protein-tyrosine Phosphatase 1B Deficiency Reduces Insulin Resistance and the Diabetic Phenotype in Mice with Polygenic Insulin Resistance* (2007) (65)
Hepatic oxidative stress promotes insulin-STAT-5 signaling and obesity by inactivating protein tyrosine phosphatase N2. (2014) (64)
Sticking It to Cancer with Molecular Glue for SHP2. (2016) (63)
PTP1B regulates non-mitochondrial oxygen consumption via RNF213 to promote tumour survival during hypoxia (2016) (63)
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. (2010) (62)
Identification of the Erythropoietin Receptor Domain Required for Calcium Channel Activation* (1999) (62)
Different Signaling Roles of SHPTP2 in Insulin-induced GLUT1 Expression and GLUT4 Translocation (*) (1995) (59)
SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth (2006) (58)
Regulation of Signaling at Regions of Cell-Cell Contact by Endoplasmic Reticulum-Bound Protein-Tyrosine Phosphatase 1B (2012) (57)
Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11) (2014) (57)
Growth factor-inducible alternative splicing of nontransmembrane phosphotyrosine phosphatase PTP-1B pre-mRNA. (1993) (56)
Avian erythroblastosis virus produces two mRNA's (1980) (56)
Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome (2014) (56)
Resveratrol Inhibits Angiotensin II- and Epidermal Growth Factor-Mediated Akt Activation: Role of Gab1 and Shp2 (2005) (55)
ADAP is required for normal αIIbβ3 activation by VWF/GP Ib-IX-V and other agonists (2007) (55)
Phosphorylated α-Actinin and Protein-tyrosine Phosphatase 1B Coregulate the Disassembly of the Focal Adhesion Kinase·Src Complex and Promote Cell Migration* (2006) (54)
Molecular analysis of the c-myc locus in normal tissue and in avian leukosis virus-induced lymphomas (1982) (52)
Peroxiredoxin-controlled G-CSF signalling at the endoplasmic reticulum–early endosome interface (2011) (52)
Overexpression, purification, and characterization of SHPTP1, a Src homology 2-containing protein-tyrosine-phosphatase. (1993) (52)
B cell antigen receptor-evoked calcium influx is enhanced in CD22-deficient B cell lines. (1997) (52)
Tyrosine Phosphorylation of the Proto-Oncoprotein Raf-1 Is Regulated by Raf-1 Itself and the Phosphatase Cdc25A (1999) (51)
Use of a general purpose mammalian expression vector for studying intracellular protein targeting: identification of critical residues in the nuclear lamin A/C nuclear localization signal. (1993) (51)
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. (2005) (50)
A suggested role for mitochondria in Noonan syndrome. (2010) (48)
Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). (1992) (47)
A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation. (2001) (47)
Scaffolding adapter Grb2-associated binder 2 requires Syk to transmit signals from FcepsilonRI. (2006) (47)
Phosphorylation of Protein-tyrosine Phosphatase PTP-1B on Identical Sites Suggests Activation of a Common Signaling Pathway during Mitosis and Stress Response in Mammalian Cells* (1997) (46)
Altered Glucose Homeostasis in Mice with Liver-specific Deletion of Src Homology Phosphatase 2* (2010) (46)
Real-time NMR Study of Three Small GTPases Reveals That Fluorescent 2′(3′)-O-(N-Methylanthraniloyl)-tagged Nucleotides Alter Hydrolysis and Exchange Kinetics* (2009) (45)
Methods to monitor classical protein‐tyrosine phosphatase oxidation (2013) (45)
Receptor-type protein-tyrosine phosphatase mu is expressed in specific vascular endothelial beds in vivo. (1999) (44)
Integration of Growth Factor, Extracellular Matrix, and Retinoid Signals during Bronchial Epithelial Cell Differentiation (1998) (44)
Macrophages require Skap2 and Sirp&agr; for integrin-stimulated cytoskeletal rearrangement (2012) (43)
Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy. (2020) (42)
Localization of the cellular oncogenes ABL, SIS, and FES on human germ-line chromosomes. (1984) (42)
SOS1 mutations are rare in human malignancies: Implications for Noonan syndrome patients (2008) (41)
Flow-Cytometric Phosphoprotein Analysis Reveals Agonist and Temporal Differences in Responses of Murine Hematopoietic Stem/Progenitor Cells (2008) (41)
Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways. (2003) (41)
Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21 (2020) (40)
Noonan Syndrome/Leukemia-associated Gain-of-function Mutations in SHP-2 Phosphatase (PTPN11) Enhance Cell Migration and Angiogenesis* (2009) (40)
Inhibition of IFN-α signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway (2005) (40)
G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase. (2011) (40)
Off‐target inhibition by active site‐targeting SHP2 inhibitors (2018) (39)
ADAP is required for normal alphaIIbbeta3 activation by VWF/GP Ib-IX-V and other agonists. (2007) (39)
Enhanced Retinal Insulin Receptor-activated Neuroprotective Survival Signal in Mice Lacking the Protein-tyrosine Phosphatase-1B Gene* (2010) (39)
Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis. (2013) (39)
Epithelial Protein-Tyrosine Phosphatase 1B Contributes to the Induction of Mammary Tumors by HER2/Neu but Is Not Essential for Tumor Maintenance (2011) (38)
Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies (2016) (38)
Antagonism between binding site affinity and conformational dynamics tunes alternative cis-interactions within Shp2 (2013) (37)
Genetic and cellular mechanisms of oncogenesis (2007) (37)
PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. (2014) (37)
SH2 Domain-Containing Protein-Tyrosine Phosphatases (2010) (36)
Retroviral gene expression. (1981) (36)
Uroporphyrinogen Decarboxylase Is a Radiosensitizing Target for Head and Neck Cancer (2011) (36)
Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. (2017) (35)
Ventromedial hypothalamus-specific Ptpn1 deletion exacerbates diet-induced obesity in female mice. (2014) (35)
The signaling adaptor GAB1 regulates cell polarity by acting as a PAR protein scaffold. (2012) (35)
Hepatocyte-Specific Ptpn6 Deletion Protects From Obesity-Linked Hepatic Insulin Resistance (2012) (34)
The Protein Tyrosine Phosphatase Receptor Delta Regulates Developmental Neurogenesis. (2020) (34)
The Gp1ba-Cre transgenic mouse: a new model to delineate platelet and leukocyte functions. (2019) (34)
Tyrosine phosphatase SHP‐2 is a mediator of activity‐dependent neuronal excitotoxicity (2005) (34)
Increased BRAF Heterodimerization Is the Common Pathogenic Mechanism for Noonan Syndrome-Associated RAF1 Mutants (2012) (34)
Assay to visualize specific protein oxidation reveals spatio-temporal regulation of SHP2 (2017) (33)
Distinct populations of tumor-initiating cells derived from a tumor generated by rat mammary cancer stem cells (2008) (33)
A Nomenclature for Signal Regulatory Protein Family Members (2005) (32)
The Skap-hom dimerization and PH domains comprise a 3'-phosphoinositide-gated molecular switch. (2008) (32)
Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth (2018) (31)
Diverse levels of sequence selectivity and catalytic efficiency of protein-tyrosine phosphatases. (2014) (31)
A ERK/RSK‐mediated negative feedback loop regulates M‐CSF–evoked PI3K/AKT activation in macrophages (2017) (30)
The DNA binding domain of retinoic acid receptor beta is required for ligand-dependent suppression of proliferation. Application of general purpose mammalian coexpression vectors. (1994) (30)
Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands. (2004) (29)
Hepatocyte‐specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet‐induced obesity: Potential role of PPARγ (2014) (29)
Selective and noncovalent targeting of RAS mutants for inhibition and degradation (2021) (29)
SHP2 regulates skeletal cell fate by modifying SOX9 expression and transcriptional activity (2018) (29)
Inhibition of IFN-alpha signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway. (2005) (28)
Phosphatidylinositol 3-Kinase p85α Subunit-Dependent Interaction with BCR/ABL-Related Fusion Tyrosine Kinases: Molecular Mechanisms and Biological Consequences (2005) (28)
Biologically-Targeted Detection of Primary and Micro-Metastatic Ovarian Cancer (2013) (27)
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC (2021) (27)
The current state of the art and future trends in RAS-targeted cancer therapies (2022) (26)
Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer (2007) (26)
The sixth international RASopathies symposium: Precision medicine—From promise to practice (2019) (25)
Dominant Role of the Protein-Tyrosine Phosphatase CD148 in Regulating Platelet Activation Relative to Protein-Tyrosine Phosphatase-1B (2012) (25)
Isolation of 16L virus: a rapidly transforming sarcoma virus from an avian leukosis virus-induced sarcoma. (1982) (25)
Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer (2019) (25)
Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia. (2018) (25)
Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles (2016) (24)
Evidence for a multipotent mammary progenitor with pregnancy-specific activity (2013) (23)
CD22 Is a Functional Ligand for SH2 Domain-containing Protein-tyrosine Phosphatase-1 in Primary T Cells* (2004) (23)
SHP2 Is Required for BCR-ABL1-Induced Hematologic Neoplasia (2017) (23)
Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. (2017) (23)
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer (2020) (23)
T cell protein tyrosine phosphatase (TCPTP) deficiency in muscle does not alter insulin signalling and glucose homeostasis in mice (2012) (23)
A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. (2018) (23)
Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner (2018) (23)
Protein Tyrosine Phosphatases in Cancer (2016) (22)
Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival (2018) (22)
N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer. (2019) (21)
Gu, H. et al. Essential role for Gab2 in the allergic response. Nature 412, 186-190 (2001) (21)
Liver-Specific Deletion of Protein-Tyrosine Phosphatase 1 B ( PTP 1 B ) Improves Metabolic Syndrome and Attenuates Diet-Induced ER Stress (2008) (21)
Piecing Together a Broken Tumor Suppressor Phosphatase for Cancer Therapy (2020) (21)
Signal transduction: An eye on organ development (2003) (20)
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer. (2021) (19)
Molecular network analysis of phosphotyrosine and lipid metabolism in hepatic PTP1b deletion mice. (2013) (19)
SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations (2021) (18)
Catalytic dysregulation of SHP2 leading to Noonan syndromes impacts on platelet signaling and functions. (2019) (18)
Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome (2017) (18)
The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning (2019) (18)
Predators increase the risk of catastrophic extinction of prey populations (2001) (18)
Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. (2016) (17)
Integrated analysis of proteome, phosphotyrosine‐proteome, tyrosine‐kinome, and tyrosine‐phosphatome in acute myeloid leukemia (2017) (17)
Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase ε. (2020) (17)
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. (2020) (16)
Advances in Brief Activating Mutations of the Noonan Syndrome-Associated SHP 2 / PTPN 11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia (2004) (14)
Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts (2017) (13)
Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1)* (2016) (13)
Identification of a Domain in the β Subunit of the Type I Interferon (IFN) Receptor That Exhibits a Negative Regulatory Effect in the Growth Inhibitory Action of Type I IFNs* (1998) (13)
Differential regulation of FGFR3 by PTPN1 and PTPN2 (2015) (12)
Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. (2018) (11)
The third international meeting on genetic disorders in the RAS/MAPK pathway: Towards a therapeutic approach (2015) (11)
Essential role for Ptpn 11 in survival of hematopoietic stem and progenitor cells (2011) (11)
Role of PTPN11 (SHP2) in Cancer (2016) (11)
Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy (2021) (9)
Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions (2020) (8)
Leukemogenic Ptpn11 Allele Causes Defective Erythropoiesis in Mice (2014) (7)
Regulation of Kidney Development by Shp2: An Unbiased Stereological Analysis (2010) (7)
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity (2019) (7)
Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening (2021) (7)
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy (2022) (6)
Both Fallopian Tube and Ovarian Surface Epithelium Can Act as Cell-of-Origin for High Grade Serous Ovarian Carcinoma (2018) (6)
From an orphan disease to a generalized molecular mechanism (2013) (6)
CHAPTER 118 – SH2-Domain-Containing Protein–Tyrosine Phosphatases (2003) (5)
PTPN11 loss-of-function mutations in the pathogenesis of metachondromatosis (2013) (5)
Tyrosine Phosphorylation of Runx1 In Megakaryocytes by Src Family Kinases (2010) (4)
Moyamoya Disease-Associated RNF213 Alleles Encode Dominant Negative Alleles That Globally Impair Ubiquitylation (2020) (4)
Tyrosyl phosphorylation toggles a Runx1 switch. (2012) (4)
Abstract B48: Feasibility study of molecular profiling (MP) in patients (Pts) with advanced solid cancers using targeted mutation analysis and targeted exome sequencing. (2011) (3)
Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions. (2020) (3)
CD22 is a functional ligand for SHP-1 in primary T cells (2004) (3)
Off-target inhibition by active site-targeting SHP2 inhibitors (2018) (3)
Avian lymphoid leukosis is correlated with the appearance of discrete new RNAs containing viral and cellular genetic information. (1981) (2)
Scaffolding Adapter Grb 2-Associated Binder 2 Requires Syk to Transmit Signals from Fc RI 1 (2006) (2)
MMD-associated RNF213 SNPs encode dominant-negative alleles that globally impair ubiquitylation (2022) (2)
SHP2 Inhibition Abrogates MEK inhibitor Resistance in Multiple Cancer Models (2018) (2)
Ontogeny and Vulnerabilities of Lapatinib Drug-Tolerant Persisters in HER2+ Breast Cancer (2020) (2)
Abstract A2-07: Integrative functional genomics of breast cancer (2015) (2)
Elevated Hypothalamic TCPTP in Obesity Contributes to Cellular Leptin Resistance. (2012) (2)
SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors (2020) (2)
U.S. Biomedical Research Needs More Immigrant Scientists, Not Fewer! (2020) (2)
Mathematical Models of Protein Kinase (2002) (2)
Signal transfer in human protein tyrosine phosphatase PTP1B from allosteric inhibitor P00058 (2021) (2)
Eruptions linked to El Niño (2003) (2)
A Noncatalytic, Ras-Independent Function of SHP-2 Is Essential in Hematopoietic Progenitors. (2007) (2)
Correction: Adipocyte-Specific Protein Tyrosine Phosphatase 1B Deletion Increases Lipogenesis, Adipocyte Cell Size and Is a Minor Regulator of Glucose Homeostasis (2012) (2)
Noonan syndrome causing-SHP2 mutants inhibit IGF-I release via GH-induced ERK1/2 hyper-activation, which contributes to short stature (2012) (2)
Activated Thiol Sepharose‐based proteomic approach to quantify reversible protein oxidation (2019) (2)
Alfred Gropp (1924–1983) (1984) (2)
Cancer: Bad neighbours cause bad blood (2016) (2)
Distinct cancer-associated fibroblast states drive clinical outcomes in high-grade serous ovarian cancer and are regulated by TCF21 (2019) (1)
Optimal Strategies for Therapy and Screening (2021) (1)
Shp1 regulates T cell homeostasis by antagonizing IL-4 signalling (P1312) (2013) (1)
The PI3K catalytic subunit p110-delta is a crucial mediator of leukemia-associated mutant PTPN11 -induced GM-CSF hypersensitivity (2012) (1)
Corrigendum: Neuronal PTP1B regulates body weight, adiposity and leptin action (2010) (1)
Improved Glucose Homeostasis in Mice with Muscle-Speciﬁc Deletion of Protein-Tyrosine Phosphatase 1B (cid:1) (2007) (1)
Corrigendum to: Off‐target inhibition by active site‐targeting SHP2 inhibitors (2019) (1)
Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition. (2023) (1)
Cellular and bioenergetic dysfunction induced by loss of the Wolfram Syndrome protein, Miner1, can be reversed by treatment with N-acetylcysteine (2013) (1)
Supplemental Materials and Methods for : Essential gene profiles in breast , pancreas and ovarian cancer cells (2011) (1)
The Physiological and Molecular Consequences of Adipocyte-Specific Protein Tyrosine Phosphatase 1B Deletion in C57BL/6 Mice (2010) (1)
Abstract #181: Identification and characterization of serous ovarian cancer-initiating cells (2009) (1)
Distinct GAB 2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL 1 (2016) (1)
Computational Modeling of Ovarian Cancer Reveals Optimal Strategies for Therapy and Screening (2019) (1)
Abstract PR07: Integrative functional genomics of breast cancer (2013) (1)
Inducible Expression of Leukemia-Associated Shp2 (Ptpn11) Affects Multiple Stages of Hematopoiesis and Causes a Fatal Myeloproliferative Disorder (MPD) in Mice (2007) (1)
Computational Modeling of Ovarian Cancer Reveals Optimal Strategies for Therapy and Screening (2019) (1)
Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in HLRCC (2018) (1)
Computational Modeling of Ovarian Cancer Reveals Optimal Strategies for Therapy and Screening (2019) (1)
Directed Self-Organization of Human and Non-Human Primate Heart Muscle Organoids from Pluripotent Stem Cells (2019) (1)
Molecular effects of Noonan syndrome-associated RAF1 mutants with increased or decreased kinase activity (2011) (0)
Abstract 18711: The Adaptor Protein Skap2 is Required for Integrin-Mediated Signaling in Macrophages (2010) (0)
Abstract B34: Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer (2012) (0)
Abstract LB-302: PTP1B regulates the Moyamoya disease-associated E3 ligase, RNF213 and cellular dioxygenase activity to allow breast tumor survival in hypoxia (2015) (0)
Animal Models for Noonan Syndrome and Related Disorders (2009) (0)
Title: Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma Running Title: Oxidation of PTPN12 Drives ABL1 Activation in HLRCC (2018) (0)
Abstract A29: The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies (2020) (0)
Protein-tyrosine-phosphatase SHPTP 2 couples platelet-derived growth factor receptor 18 to Ras ( Src homology 2 / tyrosne kinase / dgnal anduction ) (0)
Abstract 1238: Gab1 regulates epithelial cell polarity and scattering by acting as a platform for PAR proteins (2012) (0)
PROTEIN TYROSINE PHOSPHATASE 1 B ( PTP 1 B ) DEFICIENCY REDUCES INSULIN RESISTANCE AND THE DIABETIC PHENOTYPE IN MICE WITH POLYGENIC INSULIN RESISTANCE (2007) (0)
Inside-Out Signaling through ADAP Is Required for VWF-GPIb-IX-V Mediated Integrin AIibb3 Activation. (2005) (0)
PLATELETS AND THROMBOPOIESIS Megakaryocyte-speci ﬁ c deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function (2013) (0)
Abstract 141: Deletion of Ptpn11 (Shp2) in Cardiomyocytes Leads to Dilated Cardiomyopathy (2007) (0)
OVEREXPRESSION OF PROTEIN TYROSINE PHOSPHATASE-1 B IN ADIPOCYTES INHIBITS INSULIN-STIMULATED PHOSPHOINOSITIDE 3-KINASE ACTIVITY WITHOUT ALTERING GLUCOSE TRANSPORT OR AKT / PKB ACTIVATION (2000) (0)
Crystal Structure of a N-terminal Fragment of SKAP-Hom Containing Both the Helical Dimerization Domain and the PH Domain (2005) (0)
Enhanced Insulin Receptor Activated Neuroprotective Survival Signal in Mice Lacking the Protein Tyrosine Phosphatase-1B Gene in Rod Photoreceptor Cells (2008) (0)
Abstract PR04: The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies (2019) (0)
Phosphatidylinositol-3-Kinase p110d Uniquely Promotes Gain-Of-Function PTPN11-Induced GM-CSF Hypersensitivity In a Model Of Juvenile Myelomonocytic Leukemia (2013) (0)
Redox Regulation of PTPs in Metabolism: Focus on Assays (2013) (0)
Abstract 140: A novel signature of mesenchymal stromal cells in high-grade serous ovarian carcinoma (2018) (0)
Abstracts of papers presented at the 1997 Meeting on Tyrosine Phosphorylation & Cell Signaling, May 7-May 11, 1997 (1997) (0)
Crystal Structure of the PH domain of SKAP55 (2005) (0)
The role of host c-onc genes in viral and non-viral neoplasia. (1983) (0)
SHP-1 dependent and independent suppression of colitis by a CEACAM1 isoform expressing a long cytoplasmic tail (2003) (0)
Abstract LB-338: SHP2 inhibition enhances sensitivity to MEK inhibitors in multiple resistant cancer models (2018) (0)
Abstract 4296A: Myeloproliferative disease induced by leukemogenic Ptpn11 (Shp-2) phosphatase arises from hematopoietic stem cells (2010) (0)
Crystal Structure of the PH Domain of SKAP-Hom with 8 Vector-derived N-terminal Residues (2005) (0)
Abstract B020: Creating actionable neoantigens by design with KRAS(G12C) covalent inhibitors (2023) (0)
Molecular and functional heterogeneity of cancer associated fibroblasts in high-grade serous ovarian cancer (2019) (0)
Abstract B61: The genotype of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immune checkpoint therapies (2020) (0)
Abstract B12: The role of stromal cells in supporting tumor-initiating cells in serous ovarian carcinoma (2013) (0)
SH2-Containing PTPs (Shps) in RTK Signaling and Disease (2007) (0)
Abstract PR02: The spliceosome is a therapeutic vulnerability in MYC-driven breast cancer (2016) (0)
Impaired SHP 2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Factor Receptor-Citation (2010) (0)
Macrophage NADPH Oxidase Activation and ROS Production Is Positively Regulated By Shp2 Phosphatase Function (2014) (0)
In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1-mutant lung cancer (2023) (0)
HSC-Independent Yolk Sac Progenitors Bear Hallmarks of JMML in a PTPN11D61Y Mouse Model (2014) (0)
Ovarian high grade serous cancer xenografts as pre-clinical models of response to chemotherapy (2014) (0)
Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL (2008) (0)
Addendum: Neuronal PTP1B regulates body weight, adiposity and leptin action (2010) (0)
Hidesaburo Hanafusa 1929–2009 (2009) (0)
Targeting uroporphyrinogen decarboxylase for head and neck cancer treatment (2013) (0)
Activated thiol Sepharose-based proteomic approach to globally quantify protein oxidation (2019) (0)
Mechanism for the learning disability in RAS-ERK signaling-associated neurodevelopmental disorder (2019) (0)
Assay to visualize specific protein oxidation reveals spatio-temporal regulation of SHP2 (2017) (0)
Abstract 4303: Definitive identification and characterization of ovarian cancer-initiating cells (2010) (0)
Role of Gab2 in Allergic Response (2001) (0)
Abstract 3318: Phenotypic heterogeneity and instability of tumor-initiating cells in high-grade serous cancer (2012) (0)
Integrative analysis of the mutational landscape of mouse and human AML identifies functionally relevant leukemia disease alleles (2015) (0)
Abstract SY35-02: Phenotypic heterogeneity and instability of human serous ovarian cancer tumor-initiating cells (2012) (0)
Abstract 20130: Hypertrophic Cardiomyopathy in RAF1 Mutant-associated Noonan Syndrome Requires Complex Cellular Interplay (2015) (0)
Raymond L. Erikson (1936–2020) (2020) (0)
Myelopoiesis Requires a Noncatalytic, Ras-Independent Function of SHP-2. (2006) (0)
Abstract AP17: MOLECULAR AND FUNCTIONAL HETEROGENEITY OF CANCER ASSOCIATED FIBROBLASTS IN HIGH-GRADE SEROUS OVARIAN CANCER (2019) (0)
Abstract 80: Activated SHP2 collaborates with MYCN in neuroblastoma tumorigenesis (2014) (0)
IMPAIRED SHP2-MEDIATED ERK ACTIVATION CONTRIBUTES TO GEFITINIB SENSITIVITY OF LUNG CANCER CELLS WITH EGFR-ACTIVATING MUTATIONS (2010) (0)
New pROSpects for PTP1B: micro-managing oncogene-induced senescence. (2014) (0)
Neuronal Protein Tyrosine Phosphatase 1B Deﬁciency Results in Inhibition of Hypothalamic AMPK and Isoform-Speciﬁc Activation of AMPK in Peripheral Tissues (cid:1) † (2009) (0)
Activating Shp2 Mutations Cause Progressive Myeloproliferative Disorder in Mice. (2006) (0)
Abstract PR12: Genetic aberrations dictate distinct tumor immune landscape and chemosensitivity in HGSOC (2020) (0)
Title Distinct GAB 2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL 1 Permalink (2016) (0)
Expression of Leukemogenic Ptpn11 Causes a Fatal Myeloproliferative Disorder by Affecting Multiple Stages of Hematopoiesis (2008) (0)
Abstract 659: Mechanisms of resistance to SHP2 inhibition (2022) (0)
Abstract 1232: Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer (2012) (0)
Abstract PR05: Development of new immune therapy combinations for ovarian cancer using genetically defined organoid platform (2019) (0)
Structural and Signaling Requirements for Transformation Mediated by Shp2 Mutants. (2005) (0)
Abstract 12827: Mouse Model of LEOPARD Syndrome Reveals a Dominant Negative Function of the PTPN11 (Shp2) Mutation and a Mechanism of Regulation and Therapy for Hypertrophic Cardiomyopathy (2010) (0)
Abstract IA20: Analyzing the cellular basis for heterogeneity in serous ovarian carcinoma (2013) (0)
Oncogenic Ras Requires SHP-2 To Induce Myeloproliferative Disease (MPD). (2005) (0)
Abstract 5084: Functional genomic classification of breast cancer using pooled lentivirus shRNA screens (2012) (0)
Abstract B2-06: Computational modeling of serous ovarian carcinoma dynamics: Implications for screening and therapy (2015) (0)
Abstract LB-230: A prospective clinical trial to evaluate DNA sequencing as a diagnostic tool to guide cancer therapy: results from the initial 50 patients (2012) (0)
An activated SHP-2 mutant that causes noonan syndrome and is associated with cognitive impairments pertubs cell fates of cerebral cortex precursors (2006) (0)
ADAP is required for normal (cid:1) IIb (cid:2) 3 activation by VWF/GP Ib-IX-V and other agonists (2007) (0)
Abstract SY15-01: Cellular context-specific tumor suppression by PTPN11 (2012) (0)
Abstract SSY01-03: An RNAi screen identifies a heme biosynthetic mediator as a novel radiosensitizing target for head and neck cancer (2010) (0)
Abstract 1352: Shp2 is required for CML initiation and maintenance (2012) (0)
Proteomic Dynamics of Breast Cancers Identifies Potential Therapeutic Protein Targets (2022) (0)
Twohumanc-one genesarelocated onthelongarmof chromosome 8 (oncogenes/gene mapping/cancer/chromosomal translocations/cytogenetics) (1982) (0)
Abstract PR16: Computational modeling of serous ovarian carcinoma dynamics: Implications for screening and therapy. (2016) (0)
Insulin Receptor Survival Signaling in Rod Photoreceptors Is Regulated Through Rhodopsin-Controlled Protein Tyrosine Phosphatase 1B Activity (2009) (0)
Activation of Cellular Onc (C-ONC) Genes: A Common Pathway for Oncogenesis (1983) (0)
Genome-wide CRISPR/Cas9 Screens Reveal Shared and Bespoke Mechanisms of Resistance to SHP2 inhibition (2022) (0)
Mechanism of Oncogenesis by Leukemia-Associated Mutants of Shp2 (PTPN11). (2004) (0)
Abstract PR01: Functional characterization of breast cancer using pooled lentivirus shRNA screens (2013) (0)
Shp2‐dependent and ‐independent signals regulating epithelial cell scattering and invasion (2006) (0)
A family oftransmembrane proteins withhomology tothe MET-hepatocyte growthfactor receptor (1996) (0)
TCPTP-deficiency in muscle does not alter insulin signalling and glucose homeostasis. (2012) (0)
Abstract AP03: DISTINCT CELL/TISSUE SOURCES OF HIGH-GRADE SEROUS OVARIAN CANCER (2019) (0)
Abstracts of papers presented at the 2001 Meeting on Tyrosine Phosphorylation & Cell Signaling, May 16-May 20, 2001 (2001) (0)
Abstract 1889: Allosteric inhibition of SHP2 prevents adaptive resistance to MEK inhibition in neurofibromatosis type 1 associated malignant peripheral nerve sheath tumors (2020) (0)
Evidence for a multipotent mammary progenitor with pregnancy-specific activity (2013) (0)
The G-CSF Receptor Requires Gab2-Mediated Recruitment of the Tyrosine Phosphatase Shp2 to Promote Lyn-Dependent Proliferation. (2010) (0)
Determinants of specificity in phosphoprotein/ SH2 domain interactions (1994) (0)
PTP-1B Is the Protein Tyrosine Phosphatase That Initiates Integrin αIIbβ3 Outside-In Signaling in Platelets. (2004) (0)
Abstract PR1: Development of new immune therapy combinations for ovarian cancer using genetically defined organoid platform (2020) (0)
Crystal Structure of the PH Domain of SKAP-Hom (2005) (0)
Two human cone genes are located on the long arm of chromosome 8 ( oncogenes / gene mapping / cancer / chromosomal translocations / cytogenetics ) (0)
Abstract B43: Role of activated SHP2 in high-risk neuroblastoma pathogenesis (2014) (0)
Dual inhibition of SHP2 and autophagy suppresses NF1-associated Malignant Peripheral Nerve Sheath Tumors (2022) (0)
Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia (2023) (0)
Vitamin C Enhances PARPi Efficacy for the Treatment of AML (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Benjamin G. Neel?

Benjamin G. Neel is affiliated with the following schools:

Benjamin G. Neel's Academic­Influence.com Rankings

Benjamin G. Neel's Degrees

Why Is Benjamin G. Neel Influential?

Benjamin G. Neel's Published Works

Published Works

What Schools Are Affiliated With Benjamin G. Neel?

Benjamin G. Neel's AcademicInfluence.com Rankings